TrialJournal for immunotherapy of cancer2026

Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer.

Dung T Le et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.